GlassScriptPhysician profile
Leana Karam
NPI 1134969660
$4,912.28
in general payments reported to CMS, 2019-2025
23 companies · $3,689 in 2025
The $3,689 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,223 · 2025: $3,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,700 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,700.33 |
| Education | $211.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.15 | 2024-2025 | |
| Janssen Biotech, INC. | $670.83 | 2024-2025 | Tremfya |
| Incyte Corporation | $461.94 | 2024-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $415.85 | 2024-2025 | |
| Amgen INC. | $354.79 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $327.85 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $286.85 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $239.43 | 2024-2025 | Dupixent |
| Organon LLC | $237.25 | 2025 | Vtama, Hadlima |
| Lilly USA, LLC | $214.68 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $177.80 | 2024-2025 | Adbry, Spevigo |
| Sun Pharmaceutical Industries INC. | $174.19 | 2024-2025 | |
| Galderma Laboratories, L.P. | $77.58 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $72.33 | 2024-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $71.26 | 2024 | Vtama |
| Fresenius Kabi USA, LLC | $59.56 | 2024-2025 | Adalimumab-Aacf, Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.15 | 2024-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $45.58 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $27.84 | 2024 | Poteligeo |
| Lnhc, INC | $18.33 | 2025 | Zelsuvmi |
| Pfizer INC. | $15.34 | 2025 | |
| Paratek Pharmaceuticals, INC. | $13.70 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leana Karam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.